Vivos Therapeutics

Vivos Therapeutics, Inc. is a medical technology company which engages in the development and commercialization of treatment alternatives for patients with sleep disordered breathing (SDB). Its solutions are also offered for patients with mild-to-moderate obstructive sleep apnea (OSA). The company was founded by Gurdev Dave Singh, Susan McCullough, RaeAnn Byrnes, Todd Huntsman, and R. Kirk Huntsman on July 7, 2016 and is headquartered in Highlands Ranch, CO.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q3 2022

Earnings data Q2 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Vivos Therapeutics reports revenue decline but eyes growth through FDA clearances

Vivos Therapeutics reported a decline in revenue for Q1 2024 but showcased improved operating performance and cash flow management. The company is focused on revenue growth initiatives, strategic collaborations, and expanding product access to achieve cash flow positivity by late 2024 or early 2025. Challenges include revenue decline and the need to reduce dependency on dentistry channel.

Vivos Therapeutics reports robust Q2 earnings, eyes market expansion

Vivos Therapeutics delivered a strong Q2 2024 performance with revenue growth, improved margins, and cost management driving financial stability and operational efficiency.
The company's strategic initiatives, including the alliance with a sleep clinic and FDA clearances, position it well for market expansion and revenue enhancement.
While challenges in maintaining growth and managing costs persist, Vivos has opportunities to leverage its strengths in customer loyalty, financial stability, and market reach for sustainable growth.
By focusing on revenue optimization, cost control, and strategic partnerships, Vivos aims to enhance profitability, drive innovation, and capture new market opportunities.

Vivos Therapeutics reports revenue growth and strategic expansion plans

Vivos Therapeutics showed revenue growth and improved gross profit margins in Q3 2024. Despite challenges in net loss and cash burn, the company is optimistic about achieving positive cash flow and expanding its market presence through strategic alliances.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Vivos Therapeutics, Inc. is a medical technology company which engages in the development and commercialization of treatment alternatives for patients with sleep disordered breathing (SDB). Its solutions are also offered for patients with mild-to-moderate obstructive sleep apnea (OSA). The company was founded by Gurdev Dave Singh, Susan McCullough, RaeAnn Byrnes, Todd Huntsman, and R. Kirk Huntsman on July 7, 2016 and is headquartered in Littleton, CO.

Call Scheduled for Tuesday, December 20, 2022 at 5:00 pm ET Call Scheduled for Tuesday, December 20, 2022 at 5:00 pm ET

Vivos Therapeutics Schedules Release of Second and Third Quarter 2022 Financial Results and Conference Call

New Collaboration to Increase Payer Reimbursements and Patient Access New Collaboration to Increase Payer Reimbursements and Patient Access

Vivos Therapeutics Announces New Revenue Stream Through Strategic Medical Billing Relationship with Nexus Dental Systems

Vivos expects to become current on its SEC filings in the coming weeks Vivos expects to become current on its SEC filings in the coming weeks

Vivos Therapeutics Announces Receipt of Notice from Nasdaq Regarding Late Filing of Third Quarter 2022 Quarterly Report on Form 10-Q

Detailed Analysis Finds Minimal Impact on Prior Financial Results; No Previously Reported Revenue to be Lost

Vivos Therapeutics Provides Update on Revenue Recognition Review

LITTLETON, Colo., Aug. 26, 2022 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (NASDAQ: VVOS) (“Vivos” or the “Company”) today announced that it has received a notice (“Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market (“Nasdaq”) notifying the Company that it was not in compliance with requirements of Nasdaq Listing Rule 5250(c)(1) as a result of not having timely filed its Quarterly Report on Form 10-Q for the quarter ended June 30, 2022 (the “Form 10-Q”).

Vivos Therapeutics Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q

Delay Due to Technical Revenue Recognition Analysis and Unrelated to Overall Business Health Delay Due to Technical Revenue Recognition Analysis and Unrelated to Overall Business Health

Vivos Therapeutics Provides Update on Second Quarter Earnings Delay

LITTLETON, Colo., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company'') (NASDAQ: VVOS), a medical technology company focused on developing innovative treatments for patients suffering from dentofacial abnormalities and/or mild to moderate obstructive sleep apnea (OSA) and snoring in adults, today announced that it will reschedule the release of its financial results for the second quarter ended June 30, 2022 and related conference call, both previously scheduled for Monday, August 15, 2022. Further details for the release of the second quarter financial results and subsequent conference call, expected on or before August 22, 2022, will be provided in a subsequent announcement.

Vivos Therapeutics to Reschedule Second Quarter 2022 Financial Results Conference Call

LITTLETON, Colo.--(BUSINESS WIRE)--Vivos Therapeutics Announces Multiple Regulatory Clearances in Australia for Its Entire Line of Oral Appliances

Vivos Therapeutics Announces Multiple Regulatory Clearances in Australia for Its Entire Line of Oral Appliances

Study Recently Presented at the SLEEP 2022 Annual Meeting Study Recently Presented at the SLEEP 2022 Annual Meeting

Vivos Therapeutics' SLEEP 2022 Annual Meeting Presentation Highlights Retrospective Study Demonstrating Significant Improvement in Sleep Apnea

Vivos Therapeutics, Inc. (NASDAQ:VVOS ) Q1 2022 Earnings Conference Call May 16, 2022 5:00 PM ET Company Representatives Kirk Huntsman - Chairman, Chief Executive Officer Brad Amman - Chief Financial Officer Julie Gannon - Investor Relations Officer Conference Call Participants Alex Nowak - Craig-Hallum Capital Group Scott Henry - ROTH Capital Steve Kruger - Foresight Investing Operator Good day, everyone and welcome to the Vivos Therapeutics Incorporated First Quarter 2022 Earnings Call. At this time all participants are in a listen-only mode.

Vivos Therapeutics, Inc. (VVOS) CEO Kirk Huntsman on Q1 2022 Results - Earnings Call Transcript

Call Scheduled for Monday, May 16, 2022 at 5:00 pm ET Call Scheduled for Monday, May 16, 2022 at 5:00 pm ET

Vivos Therapeutics Schedules First Quarter 2022 Financial Results Conference Call

New Pneusomnia Center in Toluca Lake, Calif., Will Combine Medical and Dental Expertise to Provide Comprehensive Care for Complex Airway Issues New Pneusomnia Center in Toluca Lake, Calif., Will Combine Medical and Dental Expertise to Provide Comprehensive Care for Complex Airway Issues

Vivos Therapeutics Opens Third U.S. Multidisciplinary Center to Treat Patients Suffering from Sleep Apnea with The Vivos Method

Vivos Therapeutics, Inc. (VVOS) CEO Kirk Huntsman on Q4 2021 Results - Earnings Call Transcript

Fourth Quarter Revenue Increased 33% Year-Over-Year  While Full Year Revenue Increased 29%

Vivos Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Operational Update

Call Scheduled for Today, Thursday, March 31, 2022 at 5:00 pm ET Call Scheduled for Today, Thursday, March 31, 2022 at 5:00 pm ET

Vivos Therapeutics Schedules Fourth Quarter and Full Year 2021 Financial Results Conference Call

Pioneer in Treating Dentofacial Abnormalities and / or Mild-to-Moderate Obstructive Sleep Apnea Ranks Among Top 10 Most Innovative Medical Device Companies of the Year Pioneer in Treating Dentofacial Abnormalities and / or Mild-to-Moderate Obstructive Sleep Apnea Ranks Among Top 10 Most Innovative Medical Device Companies of the Year

Fast Company Selects Vivos Therapeutics for 2022 “World's Most Innovative Companies” List

Vivos Therapeutics, Inc. markets a jaw repositioning device that has the potential to cure patients' mild-to-moderate obstructive sleep apnea.

Vivos Therapeutics: First Take After The Broad Market Sell-Off

HIGHLANDS RANCH, Colo., March 02, 2022 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc . (“Vivos” or the “Company'') (NASDAQ: VVOS), a medical technology company focused on developing and commercializing a suite of innovative diagnostic and treatment modalities for patients with dentofacial abnormalities and/or mild to moderate obstructive sleep apnea (OSA) and snoring, today announced that Kirk Huntsman, Chief Executive Officer, will participate in the following upcoming conferences.

Vivos Therapeutics to Participate in Upcoming Investor Conferences

Vivos' Continuous Clinical Improvement Program Yields Promising Data in AHI Score Reductions for Patients with Obstructive Sleep Apnea Vivos' Continuous Clinical Improvement Program Yields Promising Data in AHI Score Reductions for Patients with Obstructive Sleep Apnea

Vivos Therapeutics Files for US Patent on Proprietary New Clinical Protocols After Seeing Further Significant Improvement in Reduction of Key Sleep Apnea Metric

BioDelivery Sciences

Bon Natural Life Ltd

Here are three penny stocks you should add to your watchlist The post These 3 Penny Stocks Exploded Today, Here's Why appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

These 3 Penny Stocks Exploded Today, Here's Why

The stock price of Vivos Therapeutics Inc (NASDAQ: VVOS) increased by over 35% during intraday trading today. This is why it happened.

Vivos Therapeutics Stock (VVOS): Why The Price Substantially Went Up Today

Gamida Cell Ltd

Splash Beverage Group

Several penny stocks are on the move Wednesday and we're diving into the hot news behind that momentum with a quick dive into the space. The post Hot Penny Stocks: What's Moving VVOS, GMDA and SBEV Higher Today?

Hot Penny Stocks: What's Moving VVOS, GMDA and SBEV Higher Today?

Vivos Therapeutics Inc (NASDAQ:VVOS) announced significant increases across several key metrics for its SleepImage Home Sleep Apnea Tests (HST). In particular, for the quarter ended December 31, 2021, versus the three months ended December 31, 2020, Vivos reported an 18 times increase in the total number of HSTs given across the network of Vivos trained dentists (known as Vivos Integrated Practices or VIPs).

Why Are Vivos Therapeutics Shares Surging Today?

Phunware Inc

Small cap stocks to watch after Trump bump hits penny stocks The post 4 Penny Stocks To Watch After DWAC Stock Wakes Up Small Caps appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

4 Penny Stocks To Watch After DWAC Stock Wakes Up Small Caps

Vivos Also Announces Improved Pricing Agreement With SleepImage

News for Vivos Therapeutics Stock (VVOS)